Afferi, L, Territo, A, Gallioli, A, Verri, P, Basile, G, Uleri, A, Cannoletta, D, Casadevall, M, Diana, P, Gavrilov, P, Arce, Y, Gaya, JM, Palou, J, Arrea, FA, Breda, A. Ex-vivo digital pathological imaging with the Vivascope confocal microscopy for intraoperative diagnostics during ureterorenoscopy for upper tract urothelial cancer. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS. 2026; 44(2)DOI:10.1016/j.urolonc.2025.11.009. PMID:41372082. IF:2.300(Q2/5D).

Batista, FD, Carcamo, PM, Nelson, E, Neto, ABD, Tsuha, DH, Lahdo, V, dos Santos, VR, Ribeiro, GS, Lopes, RD, Amadeu, P, Blanco, MVFM, da Costa, TR, Chalegre, KDD, Riback, TIS, da Silva, CC, Ranzani, OT, Cummings, DAT, Andrews, JR, Ko, AI, Hitchings, MDT, Anders, KL, Moreira, LA, Gonçalves, CCM, Croda, J. The impact of large-scale release of Wolbachia mosquitoes on dengue incidence in Campo Grande, Brazil: an ecological study. Lancet Regional Health-Americas. 2026; 54DOI:10.1016/j.lana.2025.101327. PMID:41438239. IF:(Q/D).

Buchmeier, EL, Reck, M, Girard, N, Nadal, E, Gay, CM, Filippi, AR, Martin, LW, Petersen, C, Cairns, DA, Roch, B, Attili, I, Alvarez, RA, Boyer, A, Tarruella, MM, Robinson, A, Levra, MG, Li, L, Perez, ID, Georgoulia, N, Spicer, J. Neoadjuvant (neoadj) durvalumab (D) plus chemotherapy (CT) followed by either surgery (Sx) and adjuvant D or CRT and consolidation D in patients (pts) with resectable or borderline resectable stage IIB-IIIB NSCLC: interim analysis (IA) of the phase 2 MDT-BRIDGE study. Oncology Research and Treatment. 2026; 49DOI:. PMID:. IF:1.600(Q4/9D).

Giani, C, Baldi, GG, Ljevar, S, Denu, RA, Andelkovic, V, Han, I, Brunello, A, Napolitano, A, Bhadri, VA, Scanferla, R, Garcia, AS, Abreu, MH, Campos, F, Ogura, K, Wong, DD, Bae, S, Marquina, G, Mazzocca, A, Yang, V, Nakazawa, MS, Kim, HS, Chiusole, B, Thway, K, Antonescu, C, Bellan, E, Bovée, JVMG, Davis, JL, Tos, APD, Di Blasi, E, Lazar, AJ, Sbaraglia, M, Schaefer, IM, Taverna, S, Chen, TWW, Miceli, R, Gronchi, A, Stacchiotti, S. International multicenter retrospective study on pleomorphic rhabdomyosarcoma (P-RMS), a PUSH platform study: outcome of primary localized disease. ESMO Open. 2026; 11(2)DOI:10.1016/j.esmoop.2025.106044. PMID:41564817. IF:8.300(Q1/2D).